Literature DB >> 28931

Comparative metabolism of hydrocodone in man, rat, guinea pig, rabbit, and dog.

E J Cone, W D Darwin, C W Gorodetzky, T Tan.   

Abstract

The metabolism of hydrocodone was studied in man, rat, guinea pig, rabbit, and dog. Routes of metabolism included O-demethylation, N-dealkylation, and 6-keto-reduction to the corresponding 6-alpha- and 6-beta-hydroxy metabolites, where each metabolic pathway produces an active metabolite. Mean total recovery of drug and metabolites as percentage of administered dose ranged from a low of 10.6% for the rabbit to a high of 46.8% for the guinea pig; man was intermediate at 25.7%. For man, approximately 70% of the total drug recovered was excreted in the first 24 hr, and the remainder by 72 hr. Considerable species differences were observed in the patterns of metabolism of hydrocodone. Also, stereoselectivity of 6-keto reduction to the beta-form was observed for all species in the reduction of hydrocodone and hydromorphone with the exception of the reduction of hydrocodone by man.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 28931

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  9 in total

Review 1.  Interpretation of oral fluid tests for drugs of abuse.

Authors:  Edward J Cone; Marilyn A Huestis
Journal:  Ann N Y Acad Sci       Date:  2007-03-01       Impact factor: 5.691

Review 2.  Role of active metabolites in the use of opioids.

Authors:  Janet K Coller; Lona L Christrup; Andrew A Somogyi
Journal:  Eur J Clin Pharmacol       Date:  2008-10-29       Impact factor: 2.953

3.  Evaluation of a Newly Formulated Enzyme Immunoassay for the Detection of Hydrocodone and Hydromorphone in Pain Management Compliance Testing.

Authors:  Renata Nascimento; Alphonse Poklis; Carl E Wolf
Journal:  J Anal Toxicol       Date:  2016-08-25       Impact factor: 3.367

4.  CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes.

Authors:  Mark R Hutchinson; Andrew Menelaou; David J R Foster; Janet K Coller; Andrew A Somogyi
Journal:  Br J Clin Pharmacol       Date:  2004-03       Impact factor: 4.335

Review 5.  The altered pharmacokinetics and pharmacodynamics of drugs commonly used in critically ill patients.

Authors:  A Bodenham; M P Shelly; G R Park
Journal:  Clin Pharmacokinet       Date:  1988-06       Impact factor: 6.447

6.  Opioid rotation with extended-release opioids: where should we begin?

Authors:  Srinivas Nalamachu
Journal:  Int J Gen Med       Date:  2011-12-30

7.  Preclinical and Clinical Pharmacology of Hydrocodone for Chronic Pain: A Mini Review.

Authors:  Luigi Cardia; Gioacchino Calapai; Domenico Quattrone; Cristina Mondello; Vincenzo Arcoraci; Fabrizio Calapai; Carmen Mannucci; Epifanio Mondello
Journal:  Front Pharmacol       Date:  2018-10-01       Impact factor: 5.810

8.  Current research in pathophysiology of opioid-induced respiratory depression, neonatal opioid withdrawal syndrome, and neonatal antidepressant exposure syndrome.

Authors:  Brian A Baldo
Journal:  Curr Res Toxicol       Date:  2022-06-06

Review 9.  Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy.

Authors:  Kristine R Crews; Andrew A Monte; Rachel Huddart; Kelly E Caudle; Evan D Kharasch; Andrea Gaedigk; Henry M Dunnenberger; J Steven Leeder; John T Callaghan; Caroline Flora Samer; Teri E Klein; Cyrine E Haidar; Sara L Van Driest; Gualberto Ruano; Katrin Sangkuhl; Larisa H Cavallari; Daniel J Müller; Cynthia A Prows; Mohamed Nagy; Andrew A Somogyi; Todd C Skaar
Journal:  Clin Pharmacol Ther       Date:  2021-02-09       Impact factor: 6.903

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.